Edition:
United Kingdom

Arvinas Inc (ARVN.OQ)

ARVN.OQ on NASDAQ Stock Exchange Global Select Market

24.40USD
3:42pm BST
Change (% chg)

$-0.01 (-0.04%)
Prev Close
$24.41
Open
$24.76
Day's High
$24.76
Day's Low
$24.38
Volume
6,601
Avg. Vol
62,120
52-wk High
$27.79
52-wk Low
$10.22

Latest Key Developments (Source: Significant Developments)

Arvinas Quarterly Loss Per Share $0.46
Wednesday, 8 May 2019 

May 8 (Reuters) - Arvinas Inc ::ARVINAS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE $4.0 MILLION VERSUS $4.1 MILLION.QUARTERLY LOSS PER SHARE $0.46.  Full Article

Arvinas Inc Reports Qtrly Loss Per Share $0.52
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Arvinas Inc ::ARVINAS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ARVINAS INC QTRLY LOSS PER SHARE $0.52.ARVINAS INC QTRLY REVENUE WAS $3.4 MILLION FOR QUARTER ENDED DEC 31, 2018 COMPARED TO $2.6 MILLION FOR QUARTER ENDED DEC 31, 2017.ARVINAS INC - AS OF DEC 31, 2018, CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $187.8 MILLION AS COMPARED TO $39.2 MILLION AS OF DEC 31, 2017.ARVINAS - EXPECTS CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF DEC 31, 2018 WILL BE SUFFICIENT TO FUND OPERATING EXPENSES & CAPEX INTO H1 2021.  Full Article

Arvinas Receives Authorization To Proceed IND Application For Protac Therapy
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Arvinas Inc ::ARVINAS RECEIVES AUTHORIZATION TO PROCEED FOR ITS IND APPLICATION FOR PROTAC™ THERAPY TO TREAT PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.EXPECTS TO BEGIN ENROLLMENT OF PHASE 1 CLINICAL TRIAL FOR ARV-110 IN Q1.  Full Article

Arvinas Holding Sees IPO Of 6.67 Mln Shares Of Common Stock
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Arvinas Holding Co LLC ::ARVINAS HOLDING CO SEES IPO OF 6.67 MILLION SHARES OF COMMON STOCK PRICED TO BE BETWEEN $14.00 AND $16.00 PER SHARE - SEC FILING.  Full Article

Bayer teams up with biotech firm Arvinas in deal worth up to $750 mln

FRANKFURT, June 4 German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.